Skip to main content
. 2023 Jan 20;24(3):2079. doi: 10.3390/ijms24032079

Figure 2.

Figure 2

Anti-inflammatory agents targeting the NLRP3 inflammasome and IL-1β/IL-6/CRP axis. Upstream agents targeting the NLRP3 inflammasome, interleukin (IL)-1β, and IL-6 reduce the rate of major adverse cardiovascular events, according to large RCTs. Downstream agents target translation of pCRP in the liver, CRP dissociation, and mCRP. Studies on these agents are limited to animal models and small RCTs. CRP, C-reactive protein; mCRP, monomeric C-reactive protein; pCRP, pentameric C-reactive protein; RCTs, randomized clinical trials.